

RESEARCH ARTICLE

Open Access

Cerebral hemodynamics and endothelial function in patients with Fabry disease

Tomás Segura^{1*}, Oscar Ayo-Martín¹, Isabel Gómez-Fernández¹, Carolina Andrés¹, Miguel A Barba² and José Vivancos³

Abstract

Background: Cerebral vasculopathy have been described in Fabry disease, in which altered cerebral blood flow, vascular remodelling or impairment of endothelial function could be involved. Our study aims to evaluate these three possibilities in a group of Fabry patients, and compare it to healthy controls.

Methods: Cerebral hemodynamics, vascular remodelling and systemic endothelial function were investigated in 10 Fabry patients and compared to data from 17 healthy controls. Transcranial Doppler was used to study blood flow velocity of intracranial arteries and cerebral vasomotor reactivity. For the study of vascular remodelling and endothelial function, intima-media thickness of common carotid arteries, flow-mediated dilation in brachial artery and serum levels of soluble VCAM-1, TNF- α , high-sensitive CRP and IL-6 were measured. Differences between groups were evaluated using appropriate tests.

Results: No relevant differences were observed in cerebral hemodynamic parameters, intima-media thickness or flow-mediated dilation. There was a trend for low serum levels of IL-6 and high serum levels of TNF- α and high-sensitive CRP in Fabry patients; plasma concentrations of soluble VCAM-1 were significantly higher in Fabry disease patients than in healthy volunteers ($p = 0.02$).

Conclusions: In our sample, we did not find relevant alterations of cerebral hemodynamics in Fabry disease patients. Increased levels of plasmatic endothelial biomarkers seem to be the most important feature indicative of possible vascular dysfunction in Fabry disease patients.

Keywords: Fabry disease, Hemodynamics, Chemokines, Endothelium

Background

Anderson Fabry disease (FD) (OMIM 301500) is an X-linked inherited sphingolipid storage disorder caused by deficiency of lysosomal enzyme alpha-galactosidase A (GLA). This illness is characterized by progressive accumulation of glycosphingolipids, mainly globotriaosylceramide (Gb3), in lysosomes in a variety of cell types, including renal cells, myocardial cells, heart valve fibrocytes, nervous system cells, and endothelial cells of blood vessels [1-7].

FD is associated with a broad range of clinical symptoms [3], including pain and paresthesias in the extremities, sensorineural hearing loss, angiokeratoma, corneal and lenticular opacities, hypohidrosis, cardiac and renal dysfunction,

gastrointestinal symptoms, TIA and stroke [3,5,7]. The disease can be diagnosed measuring alpha-galactosidase A activity in leukocytes or plasma and analyzing genotype (mutation analysis of GLA gene). Once the diagnosis is made, FD can be treated with enzyme replacement therapy (ERT), commercially available since 2001 [3,5,8]. Monitoring of FD progression is based on clinical, radiological, and laboratory assessments [9].

Cerebral micro- and macro-angiopathy are hallmarks of FD [6] and cerebrovascular ischemic events (brain infarctions or transient ischemic attacks) are present in over 25% of patients, and the frequency increases with age. In fact, it is probable that stroke could be the first manifestation of the disease in some patients [10] and one of the most common clinical manifestations in women [11]. An etiology of each single event is hard to identify, and it is likely to be mixed even in the same patient at

* Correspondence: tsmtsm08@yahoo.es

¹Department of Neurology, Hospital General Universitario de Albacete, C/Hermanos Falcó S/N, Albacete 02006, Spain

Full list of author information is available at the end of the article

different times: arteriolar obstruction, arteriosclerosis, arterio-arterial embolism and cardiogenic embolism are all potential mechanisms [8].

Of note, despite its potential severity, there is currently no early marker for cerebrovascular risk that allows optimization of the treatment of patients affected by FD (either hemizygotic males or heterozygotic females), nor is it possible to investigate the value of ERT in reducing that risk. Among possible markers to cerebral impairment in FD, parameters of brain hemodynamics, with controversial results, have been studied [12-15].

In this context, the aim of our study was to investigate the potential presence of alterations in cerebral hemodynamics (using transcranial Doppler to measure brain blood flow velocities and cerebral vasomotor reactivity), as well as the existence or not of vascular remodelling (measuring intima-media thickness and the distance between adventitial layers in common carotid arteries) and the presence of endothelial dysfunction (using the reactive brachial hyperaemia test and levels of endothelium released markers) in patients of both sexes diagnosed of FD in comparison with healthy volunteers.

Methods

A total of 27 subjects over age 18 years and agreeing to take part in the study were recruited and centrally studied in our neurosonology laboratory. The sample included 17 age and sex-matched healthy volunteers (12 females and 5 males, age range 18–61 years) and 10 patients diagnosed with FD (6 females and 4 males, age range 18–61 years). All patients carried a mutation associated with a classic phenotype of FD. All males had a low or very low GAL enzyme activity in plasma (between 1–15 nmol/h/mg). In women, the diagnosis had been made through the identification of a pathogenic GLA mutation on molecular genetic testing, although in three of the six women enzymatic activity was also low, less than 15 nmol/h/mg. In the Fabry group, all males and two females were receiving ERT. Three males were taking this treatment for 5 years, one since 7 years and one for 3 years. One of the females took the treatment for 5 years and the other female since one year before the study measurements.

All patients with FD were selected from the Spanish Fabry Outcome Survey (FOS) database. The work was part of a wider project, within an educational grant awarded to the Department of Neurology of Albacete General Hospital. The study complied with the ethical principles of the Spanish Fabry Outcome Survey Project protocol and was approved by the Albacete General Hospital Research Ethics Committee. All patients as well as control subjects provided informed consent.

Exclusion criteria included the existence of an unstable cardiovascular disorder, previous cerebrovascular symptoms,

anemia or severe obstructive pulmonary disease and the absence of a transcranial sonographic window.

For the study of brain hemodynamics, both determination of blood flow in brain arteries and measurement of cerebral vasomotor reactivity (CVR) were conducted using Transcranial Doppler (TCD Box, Compumedics DWL, Singen, Germany). We measured the blood flow velocity of the main intracranial arteries: the right and left middle cerebral arteries (Vmca), anterior cerebral arteries (Vaca), posterior cerebral arteries (Vpca) and the basilar artery (Vbas). Gosling's pulsatility index (PI) of these 7 intracranial arteries was calculated according to the following formula: $PI = (V_{max} - V_{min}) / V_{mean}$. CVR was also measured by TCD using as trigger stimuli a voluntary apnoea, (the so-called breath-holding test). We calculated the percentage of increase of blood flow velocity in the right middle cerebral artery after a voluntary 25-seconds apnea, as previously described [16].

In order to assess the existence of a potential vascular remodelling, we measured the intima-media thickness (IMT) of common carotid arteries (MyLab 25 Gold, Esaote, Geneve, Italy) as previously reported [17] and also the distance between adventitial layers of both common carotid arteries. We estimated the endothelial function performing the post-ischemic brachial vasodilation test (also known as flow-mediated brachial vasodilation or brachial hyperaemic vasodilation test), expressed as percentage of dilation in 60 seconds [18] and serum levels of biomarkers related with inflammation and endothelial dysfunction: soluble vascular cell adhesion molecule-1 (sVCAM-1), tumor necrosis factor- α (TNF- α), high-sensitive CRP (hs-CRP) and interleukin-6 (IL-6). Plasma levels of sVCAM-1 (ng/mL), TNF- α and IL-6 (pg/mL) were determined using specific cytokine antibodies (Biosource Europe, S.A., Belgium), while high-sensitive C-reactive protein (hs-CRP) (range 0.05 – 170 mg/L) was measured using an immunoturbidimetric assay (Tina-quant® C-reactive protein (latex) high sensitive assay, Roche, USA).

Statistical analysis

Data were analysed with SPSS for Windows (version 17.0). Continuous variables were presented as mean \pm SD. Comparisons between Fabry patients and controls were performed using the Mann-Whitney rank sum test for non-normally distributed data and the t-test for normally distributed variables. Values of $p < 0.05$ were considered significant.

Results

Demographic and baseline characteristics were similar in both groups. Age of participants was $37,5 \pm 13,4$ in FD patients and $37,7 \pm 14,0$ in control subjects (mean age \pm SD). There were no relevant differences regarding classical vascular risk factors (arterial hypertension, diabetes,

dyslipidemia) between groups: one subject of the control group had arterial hypertension, while four patients with FD versus two subjects of the control group suffered dyslipidemia. Of note, only one patient had advanced kidney disease, in whom the lowest α -Gal A activity was detected.

Brain hemodynamics

No differences were observed between groups in the flow velocities of the brain arteries or in their PI, nor in the anterior group (middle and anterior cerebral arteries) neither in the posterior ones (posterior and basilar arteries) (Table 1).

In the evaluation of cerebral vasomotor reactivity (apnea test), we only observed a tendency toward a

lower vasomotor reactivity in patients with FD than in the control group (Table 1).

Vascular remodelling

We did not find differences between groups in the thickness (IMT) of both common carotid arteries nor in the distance between adventitial layers of these arteries (Table 2). Interestingly, no atherosclerotic plaques were found in the carotid arteries in any of the studied subjects.

Endothelial dysfunction

In the study of post-ischemic brachial vasodilation, we did not find significant differences between groups in the percentage of dilation after 60 seconds (Table 2). However, concerning serum levels of biomarkers for endothelial

Table 1 Parameters of cerebral vascular function (blood flow and cerebral vasomotor reactivity)

Parameter	Healthy volunteers (n = 17)	Patients with FD (n = 10)	p value
<i>Right middle cerebral artery</i>			
Mean blood flow velocity (cm/s)	56.07 ± 10.36	56.82 ± 15.53	0.9
Maximum blood flow velocity (cm/s)	87.58 ± 16.48	86.64 ± 21.66	0.9
Pulsatility index	0.84 ± 0.15	0.80 ± 0.18	0.57
Apnea Test (%)	56.79 ± 15.68	47.25 ± 15.36	0.21
<i>Left middle cerebral artery</i>			
Mean blood flow velocity (cm/s)	59.21 ± 14.15	58.15 ± 16.95	0.9
Maximum blood flow velocity (cm/s)	94.30 ± 22.09	88.85 ± 26.64	0.6
Pulsatility index	0.89 ± 0.1402	0.83 ± 0.2161	0.4
<i>Right anterior cerebral artery</i>			
Mean blood flow velocity (cm/s)	47.90 ± 11.82	49.18 ± 13.00	0.8
Maximum blood flow velocity (cm/s)	75.97 ± 16.73	74.53 ± 25.22	0.9
Pulsatility index	0.89 ± 0.11	0.84 ± 0.21	0.4
<i>Left anterior cerebral artery</i>			
Mean blood flow velocity (cm/s)	48.95 ± 11.69	47.29 ± 16.57	0.8
Maximum blood flow velocity (cm/s)	76.66 ± 15.13	70.61 ± 25.79	0.5
Pulsatility index	0.87 ± 0.15	0.89 ± 0.23	0.8
<i>Right posterior cerebral artery</i>			
Mean blood flow velocity (cm/s)	40.93 ± 8.22	37.80 ± 11.11	0.4
Maximum blood flow velocity (cm/s)	64.85 ± 13.19	53.55 ± 18.00	0.1
Pulsatility index	0.8897 ± 0.23	0.7651 ± 0.20	0.2
<i>Left posterior cerebral artery</i>			
Mean blood flow velocity (cm/s)	37.84 ± 5.12	37.60 ± 10.11	0.9
Maximum blood flow velocity (cm/s)	59.41 ± 7.48	56.25 ± 17.09	0.5
Pulsatility index	0.86 ± 0.13	0.83 ± 0.20	0.8
<i>Basilar artery</i>			
Mean blood flow velocity (cm/s)	41.60 ± 8.14	45.38 ± 12.90	0.4
Maximum blood flow velocity (cm/s)	65.35 ± 12.52	64.02 ± 25.69	0.8
Pulsatility index	0.86 ± 0.13	0.78 ± 0.20	0.3

apnea test = breath-holding test. Data are means ± SD.

Table 2 Parameters of systemic endothelial function and vascular remodelling


Parameter	Healthy volunteers (n = 17)	Patients with FD (n = 10)	p value
IMT right common carotid artery (mm)	0.57 ± 0.07	0.60 ± 0.19	0.51
Distance between advential layers of right common carotid artery (mm)	6.25 ± 1.55	6.50 ± 0.91	0.71
IMT left common carotid artery (mm)	0.54 ± 0.94	0.62 ± 0.21	0.16
Distance between advential layers of left common carotid artery (mm)	6.45 ± 0.78	6.66 ± 0.91	0.62
Mean diameter of brachial artery (mm)	3.64 ± 0.67	3.38 ± 0.70	0.36
Brachial hyperaemic vasodilation test (60°)	16.85 ± 10.59	14.10 ± 11.62	0.54
us-CRP (mg/L)	1.74 ± 1.51	2.92 ± 1.88	0.14
IL-6 (pg/mL)	7.48 ± 2.15	6.34 ± 1.42	0.06
sVCAM-1 (ng/mL)	714.47 ± 178.22	899.50 ± 217.24	0.02
TNF-α (pg/mL)	4.41 ± 1.17	5.41 ± 1.66	0.11

IMT, intima-media thickness. Data are means ± SD. p < 0.05 compared to control patient.

dysfunction and inflammation, we found low serum levels of IL-6 and high serum levels of sVCAM-1, TNF-α and hs-CRP in Fabry patients than in healthy volunteers. Notably, in the case of sVCAM-1, statistically significant differences were observed (899.50 ng/mL in FD patients vs 714.47 ng/mL in healthy volunteers, p = 0.02) (Table 2 and Figure 1).

Discussion

The main clinical manifestations in FD consist of vascular associated complications, but the pathophysiology of the FD vasculopathy is unclear. Specifically, the exact nature of the cerebrovascular disease in FD is controversial. It has been postulated that the accumulation of glycosphingolipids in the endothelium might increase the



risk of stroke directly by provoking thickening with occlusion of the small vessels or indirectly by generating endothelial dysfunction [14]. However, there is also the possibility that the anomalous accumulation of glycosphingolipids may affect the muscle cells of the vessel wall, and/or the vegetative neurons regulating them [19]. If this latter occurred, there would be a loss of the characteristic special hemodynamics of the brain vessels, including vasoreactivity [12,14,20]. Although it would be expected that this disturbance only was able to affect the smaller vessels of the brain, the fact is that previously some authors had described the existence of hyperflow [14,21] in the basal cerebral arteries, while others found hypoflow [13]. In our study we have not found relevant differences in the blood flow parameters of the main cerebral arteries between healthy volunteers and FD patients. These findings may be related to the small sample size, although the results did not show any trend. Secondly, we studied if FD patients suffered any alteration of the cerebral vasoreactivity. We only detect a trend toward a lower vasomotor reactivity in the middle cerebral artery of patients with FD. The cerebral vasomotor reactivity is a control mechanism to regulate the brain blood supply in an attempt to ensure that the metabolism of the brain will not be affected by systemic alterations or arterial pressure variations. It achieves its function by increasing the blood flow through vasodilation of the cerebral arterioles if the systemic pressure falls or the metabolic conditions worsen. In fact, cerebrovascular reactivity damage due to autonomic dysfunction has been previously considered among the pathogenic factors of thrombotic and ischemic brain infarctions of FD [12,13], but in our group, we were not able to confirm that hypothesis. Again, these findings may be related to the small sample size or be influenced because the measures were taken at the middle cerebral artery. Thus, a recent study [15], did find a disturbed neurovascular coupling in the territory of the posterior cerebral artery, which could translate a dysfunction of cerebrovascular reactivity in the territory of that artery.

Our work was also designed to investigate whether arterial remodelling could influence the high vascular risk of Fabry patients. As such, we measured the interadventitial caliber of the carotid arteries and the thickness of the intima-media layer. We found no differences between groups. It therefore seems unlikely that macrovascular damage in the extracranial bed could be responsible for the origin of cerebrovascular disease in most Fabry patients, at least until advanced stages of disease.

Finally, we also investigated the presence of endothelial dysfunction. First, we used a test of proven value in determining endothelial dysfunction, the brachial hyperaemic vasodilation test. We did not find relevant differences between patients and controls. Previous studies

suggested a chronic alteration of the nitric oxide (NO) pathway in Fabry disease [14], but at the same time has been shown that non-NO factors determine an enhanced endothelium-dependent vasodilation in Fabry disease [22]. Thus, an event could compensate for another and the final result may be a normal brachial hyperaemic vasodilation test, as we found. Secondly, serological markers of inflammation and endothelial activation were measured. Probably the most relevant finding of our study was that, in absence of clear vascular remodelling or vasodilatory endothelial dysfunction, increased levels of endothelium-release biomarkers (sVCAM-1, hs-CRP and TNF- α) were observed in patients with FD. In the case of sVCAM-1, the differences were statistically relevant. Previous studies had also reported increased biomarker levels for endothelial activation, such as sVCAM-1, sICAM, P-selectin, E-selectin, plasminogen activator inhibitor (PAI) and endothelium derived micro-particles [23-26], thus suggesting that a local process in the vessel wall could be primarily responsible for the ischemic lesions [19]. In an *in vitro* study [25], an excess of intracellular accumulation of Gb3 induced oxidative stress and up-regulated the expression of cellular adhesion molecules (ICAM-1, VCAM-1 and E-Selectin) in vascular endothelial cells of FD patients. Reduction of endogenous Gb3 by treatment of the cells with an inhibitor of glycosphingolipid synthase or α -galactosidase A led to decreased expression of adhesion molecules. At a clinical level, a study done investigating 25 patients and 25 controls [23] showed increased concentrations of sICAM-1, sVCAM-1, P-selectin and PAI, and decreased levels of thrombomodulin in Fabry patients, thus suggesting that endothelium activation and a prothrombotic state may play a significant role in the occurrence of stroke in Fabry disease. However, in a subsequent study [24] no differences were found in ICAM-1, plasma P-selectin or plasma thrombomodulin levels between 12 patients and 15 controls, although plasmatic levels of sVCAM-1 were also significantly higher in patients with Fabry disease.

We also found higher levels of sVCAM-1, hs-CRP and TNF- α in FD patients than in healthy volunteers and in the case of sVCAM-1, the differences were statistically relevant. The VCAM-1 molecule is inducible by cytokines such as TNF- α , IL-1, and IL-4 on endothelium *in vitro* [27]. VCAM-1 mediates the adhesion of inflammatory cells to vascular endothelium and functions in leukocyte-endothelial cell signal transduction [28]. For these reasons, VCAM-1 is a valid candidate marker to measure endothelial dysfunction *in vivo*, but its high levels should be considered as an indicator of systemic endothelial dysfunction and not just a local phenomenon [19,29].

Our study has some limitations. First, the small size of our sample. FD is a rare condition and it is difficult to get a large number of patients to study (*in Spain, for*

example, little more than 100 patients have been diagnosed). Then, a complete and centralized vascular study over 10 patients should be considered of interest. Another possible limitation of this study is the pooled analysis of data from both homozygous and hemizygous FD patients and from patients receiving ERT and untreated patients. Nevertheless, in subanalyses performed only in homozygous or hemizygous alone or in treated/untreated patients, similar results were obtained (data not showed). Finally, it has been proposed that the plasmatic abnormalities in markers for endothelial activation were more likely related to renal insufficiency rather than to Fabry disease itself [30]. However, in our sample only one patient had advanced kidney disease, and both the remaining patients and controls had a glomerular filtration rate within normal limits. Excluding this sole patient in the statistical analysis did not change the differences between the groups regarding to levels of sVCAM-1. In fact, the detected value of sVCAM-1 in this patient was 662 ng/mL, below the mean value of patients and controls.

Our findings support the hypothesis that an increased endothelial inflammatory profile exists in Fabry disease patients. This proinflammatory endothelial dysfunction seems to be present in the early stages of the illness, before any sign of atheromatosis or arterial remodelling and even before any relevant alteration of the endothelium-dependent vasodilator capacity, and could be the main cause of the thrombogenicity of FD. If so, then serum biomarkers are probably better indicators than brain hemodynamic parameters to estimate the stroke risk in FD patients and to measure the efficacy of therapeutic interventions in this field.

Our results do not help to explain the special affinity of FD thrombogenicity by the brain. We cannot exclude that in patients with advanced disease a clear deterioration of cerebral hemodynamics could appear; that situation, coupled with the previous endothelial dysfunction might then explain the predominant involvement of the brain. To clarify this hypothesis, larger studies specially focused in FD patients who have already had cerebral involvement, are necessary.

Conclusions

In summary, the vasculopathy of Fabry disease has been classically attributed to the progressive deposition of Gb3 in the vascular endothelium, which could eventually lead to structural abnormalities in the vessel wall; however, our results as well as other from previous studies, allow us to hypothesize that the primary metabolic defect could induce a cascade of events leading to endothelial dysfunction that, with the progression of the disease, might promote thrombotic phenomena and cerebrovascular events. Serum biomarkers would then be probably better indicators than brain hemodynamic parameters

to estimate the stroke risk in Fabry disease and to measure the efficacy of therapeutic interventions in this field.

Abbreviations

sVCAM-1: Soluble vascular cell adhesion molecule-1; TNF- α : Tumor necrosis factor- α ; hs-CRP: High-sensitive C-reactive protein; IL-6: Interleukin-6; FD: Anderson Fabry disease; GLA: Alpha-galactosidase A; Gb3: Globotriaosylceramide; TIA: Transient ischemic attack; ERT: Enzyme replacement therapy; TCD: Transcranial doppler; FOS: Fabry outcome survey; CVR: Cerebral vasomotor reactivity; Vmca: Mean velocity of middle cerebral artery; Vaca: Mean velocity of anterior cerebral artery; Vpca: Mean velocity of posterior cerebral artery; Vbas: Mean velocity of basilar cerebral artery; PI: Pulsatility index; IMT: Intima-media thickness; NO: Nitric oxide; sICAM: Soluble intercellular adhesion molecule; PAI: Plasminogen activator inhibitor; IL-1: Interleukin-1; IL-4: Interleukin-4.

Competing interests

Dr Segura has served as a consultant for Shire Human Genetic Therapies, Inc. The other authors report no conflicts.

Authors' contributions

TS selected the patients, evaluated their clinical data, performed the statistical analysis, prepared the manuscript draft and participated in the study design. OAM analyzed the ultrasound data, participated in the study design and helped drafting the manuscript. IGF verified and evaluated the clinical data of the patients and participated in creating the database. CA helped in the selection of patients and controls and analyzed the laboratory data. MAB helped in the selection of patients and participated in the study design. JV analyzed the ultrasound data and participated in the coordination of the study. All authors read and approved the final manuscript.

Acknowledgements

The authors thank Dr. FJ Barbado and Dr. M López (Hospital Universitario La Paz de Madrid), Dr. J Herrera (Hospital General de Asturias), Dr. E Gómez (Hospital Central de Asturias), Dr. J Torras (Hospital de Bellvitge, Barcelona) and Dr M Pineda (Hospital Sant Joan de Deu, Barcelona) for their support regarding patient's information and contacting. The authors thank Shire Human Genetic Therapies, Inc. for providing an unrestricted educational grant and Nuria Piqué, PhD, (from Adelphi Spain) for her help in the preparation of the manuscript.

Author details

¹Department of Neurology, Hospital General Universitario de Albacete, C/Hermanos Falcó S/N, Albacete 02006, Spain. ²Medicine Department, Hospital General Universitario de Albacete, Albacete, Spain. ³Neurology Department, Hospital Universitario de La Princesa, Madrid, Spain.

Received: 9 January 2013 Accepted: 6 November 2013

Published: 11 November 2013

References

1. Burlina AP, Sims KB, Politei JM, Bennett GJ, Baron R, Sommer C, et al: Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. *BMC Neurol* 2011, **11**:61.
2. Celtikci B, Topçu M, Ozkara HA: Two novel alpha-galactosidase mutations causing fabry disease: a missense mutation M11V in a heterozygote woman and a nonsense mutation R190X in a hemizyote man. *Clin Biochem* 2011, **44**:809–812.
3. Lidove O, Kaminsky P, Hachulla E, Leguy-Seguín V, Lavigne C, Marie I, et al: Fabry disease 'The New great Imposter': results of the French observatoire in internal medicine departments (FIMeD). *Clin Genet* 2012, **81**:571–577.
4. Altarescu G, Elstein D: Fabry disease in an oligosymptomatic male. *Isr Med Assoc J* 2011, **13**:191–192.
5. Ramaswami U: Update on role of agalsidase alfa in management of Fabry disease. *Drug Des Devel Ther* 2011, **5**:155–173.
6. Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, et al: Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. *Stroke* 2010, **41**:863–868.
7. Alfadhel M, Sirrs S: Enzyme replacement therapy for Fabry disease: some answers but more questions. *Ther Clin Risk Manag* 2011, **7**:69–82.

8. Salvati A, Burlina AP, Borsini W: **Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement, and support therapy.** *Neurol Sci* 2010, **31**:299–306.
9. Aerts JM, Kallemeijn WW, Wegdam W, Joao Ferraz M, van Breemen MJ, Dekker N, et al: **Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibitors.** *J Inher Metab Dis* 2011, **34**:605–619.
10. Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al: **Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.** *Lancet* 2005, **366**:1794–1796.
11. MacDermot KD, Holmes A, Miners AH: **Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.** *J Med Genet* 2001, **38**:769–775.
12. Kolodny EH, Pastores GM: **Anderson-Fabry disease: extrarenal, neurologic manifestations.** *J Am Soc Nephrol* 2002, **13**(Suppl 2):S150–S153.
13. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H: **Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease.** *J Neurol* 2004, **251**:564–570.
14. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, et al: **Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.** *Circulation* 2001, **104**:1506–1512.
15. Azevedo E, Mendes A, Seixas D, Santos R, Castro P, Ayres-Basto M, Rosengarten B, Oliveira JP: **Functional transcranial Doppler: presymptomatic changes in Fabry disease.** *Eur Neurol* 2012, **67**:331–337.
16. Jiménez-Caballero PE, Segura T: **Normal values of cerebral vasomotor reactivity using the breath-holding test.** *Rev Neurol* 2006, **43**:598–602.
17. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, Csiba L, Desvarieux M, Ebrahim S, Hernandez Hernandez R, Jaff M, Kownator S, Naqvi T, Prati P, Rundek T, Sitzer M, Schminke U, Tardif JC, Taylor A, Vicaute E, Woo KS: **Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). an update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European stroke conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011.** *Cerebrovasc Dis* 2012, **34**:290–296.
18. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al: **Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the international brachial artery reactivity task force.** *J Am Coll Cardiol* 2002, **39**:257–265.
19. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE: **Vasculopathy in patients with Fabry disease: current controversies and research directions.** *Mol Genet Metab* 2010, **99**:99–108.
20. Itoh Y, Esaki T, Cook M, Qasba P, Shimoji K, Alroy J, et al: **Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase a knockout mouse model of fabry disease.** *J Neurochem* 2001, **79**:1217–1224.
21. Politei JM, Capizzano AA: **Magnetic resonance image findings in 5 young patients with Fabry disease.** *Neurologist* 2006, **12**:103–105.
22. Altarescu G, Moore DF, Pursley R, Campia U, Goldstein S, Bryant M, et al: **Enhanced endothelium-dependent vasodilation in Fabry disease.** *Stroke* 2001, **32**:1559–1562.
23. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutière B, Altarescu G, et al: **Profile of endothelial and leukocyte activation in Fabry patients.** *Ann Neurol* 2000, **47**:229–233.
24. Demuth K, Germain DP: **Endothelial markers and homocysteine in patients with classic Fabry disease.** *Acta Paediatr Suppl* 2002, **91**:57–61.
25. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, et al: **Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.** *Mol Genet Metab* 2008, **95**:163–168.
26. Gelderman MP, Schiffmann R, Simak J: **Elevated endothelial microparticles in Fabry children decreased after enzyme replacement therapy.** *Arterioscler Thromb Vasc Biol* 2007, **27**:e138–e139.
27. Osborn L: **Leukocyte adhesion to endothelium in inflammation.** *Cell* 1990, **62**:3–6.
28. Tokuhira M, Hosaka S, Volin MV, Haines GK, Katschke KJ, Kim S, et al: **Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis.** *Arthritis & Rheumatism* 2000, **43**:1122–1133.
29. Constans J, Conri C: **Circulating markers of endothelial function in cardiovascular disease.** *Clin Chim Acta* 2006, **368**:33–47.
30. Vedder AC, Biró E, Aerts JM, Nieuwland R, Sturk G, Hollak CE: **Plasma markers of coagulation and endothelial activation in Fabry disease: impact of renal impairment.** *Nephrol Dial Transplant* 2009, **24**:3074–3081.

doi:10.1186/1471-2377-13-170

Cite this article as: Segura et al.: Cerebral hemodynamics and endothelial function in patients with Fabry disease. *BMC Neurology* 2013 **13**:170.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

